Jay Cross
Chief Financial Officer of Senti Biosciences Holdings, Inc. at Senti Biosciences.
Raised on Senti Biosciences filings
$10M
of $40M offered across 1 Form D filing
- Form D filings
- 1
- Teammates
- 9
- Last filing
- Jun 4, 2026
Company
Senti Biosciences
Biotech · South San Francisco, CA
Gene medicines whose dose can be tuned after treatment
Gene medicines whose dose can be tuned after treatment
- Investors
- 1
- Still open
- $30M
Senti Biosciences filings
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Jun 4, 2026 | Debt | $10M/ $40M | Form D |
- DebtFiled Jun 4, 2026Form D$10M/ $40M
Works with
Timothy LuChief Executive Officer, Form D signerForm D signerKanya RajangamPresident, Head of Research and Development and Chief Medical Officer of Senti Biosciences Holdings, Inc.Frances D. SchulzDirector of Senti Biosciences Holdings, Inc.James J. CollinsDirector of Senti Biosciences Holdings, Inc.Brenda CooperstoneDirector of Senti Biosciences Holdings, Inc.Bryan BaumDirector of Senti Biosciences Holdings, Inc.Donald TangDirector of Senti Biosciences Holdings, Inc.Edward MathersDirector of Senti Biosciences Holdings, Inc.Feng HsiungDirector of Senti Biosciences Holdings, Inc.
